Side-by-side comparison of AI visibility scores, market position, and capabilities
Muna Therapeutics raised $75M in 2024 targeting microglial biology in Alzheimer's disease, using iPSC-derived microglia models to identify novel drug targets that modulate brain immune function.
Muna Therapeutics focuses on microglial biology — the specialized immune cells of the brain — as the key to developing disease-modifying Alzheimer's therapies beyond amyloid targeting. The company uses induced pluripotent stem cell (iPSC)-derived microglia as disease models to identify and validate novel drug targets implicated by Alzheimer's genetics (TREM2, PLCG2, BIN1, APOE). This platform enables the company to study microglial dysfunction at scale and run drug screens against human-relevant cellular models.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.